Caplin Point listed on Forbes Asia's '200 Best Under a Billion' for 2023

Caplin Point Laboratories Ltd has been recognized in Forbes Asia's 200 Best Under a Billion list for the year 2023, a compilation that underscores companies' sustained and robust performance across critical benchmarks. Carefully selected from a substantial pool of more than 20,000 publicly traded companies across the Asia-Pacific region, the chosen 200 enterprises showcase annual sales under $1 billion. The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity.

Commenting on the achievement, Mr. C.C. Paarthipan, Chairman said: "The inclusion of Caplin Point Laboratories Ltd in Forbes Asia's '200 Best Under a Billion' list for 2023 is a testament to our dedication to excellence. This marks our 6 th appearance on this list in the last decade-a prestigious achievement for an Indian pharmaceutical company. We remain focused on strengthening cash flows and ensuring consistent profitability and this recognition reaffirms our commitment to these financial goals."

Shares of Caplin Point Laboratories Limited was last trading in BSE at Rs. 1064.75 as compared to the previous close of Rs. 1008.45. The total number of shares traded during the day was 87012 in over 5548 trades.

The stock hit an intraday high of Rs. 1076.40 and intraday low of 1011.10. The net turnover during the day was Rs. 91921318.00.

Source : Equity Bulls

Keywords

CaplinPointLaboratories INE475E01026 Recognition ForbesAsia 200BestUnderaBillion